Finance News

How FDA built a case against CANARX execs offering cheap medication


How high drug costs fueled what feds call an illegal import scheme

The federal case against an alleged illegal prescription drug operation and its two top leaders earlier this month features a notable informant: the CEO of a peer company that authorities say was committing the same import violations.

John Thomas Howard, treasurer and director of a Canadian healthcare company called CANARX, was arrested in the tunnel connecting Detroit and Canada on Nov. 8 and charged with smuggling, conspiracy and importing a misbranded drug for patient use in the United States. His brother and the president of the company, Bob Howard, is wanted on similar charges and was still being sought as of last week, according to court records.

The charges mark the first criminal case by U.S. authorities against a company that’s part of a cottage industry known as alternative funding programs, or AFPs, that promise to lower or eliminate high prescription drug costs for Americans.

The cheaper medications are typically sourced from international markets, a business model that the Food and Drug Administration and Department of Homeland Security say is illegal and can put patients’ health at risk.

At issue is the unregulated nature of drugs intended for foreign markets and, in some cases, the risk of counterfeit products. And while AFPs generally argue that the importation of medication is allowable under U.S. law by individuals for personal use, authorities contend the operations go too far.

CANARX, based in Windsor, Ontario, was established in 2002 and was featured in a CNBC investigation into the booming AFP industry.

Joseph Morris, general counsel for CANARX, told CNBC last year that the business was operating legally and was confident in the safety of the prescriptions it provided. Last week, Morris told CNBC that the Howard brothers “deny all the charges against them, will defend vigorously, and expect to be vindicated in court.”

CEO turned informant

The FDA’s case against CANARX started with a tip about a similar healthcare operation called ScriptSourcing. It is detailed in a 35-page affidavit — dated Oct. 29 and unsealed last week — written by Dustin Dobbs, special agent with the FDA’s Office of Criminal Investigations.

Based in Bonita Springs, Florida, ScriptSourcing marketed its international prescription program to self-funded employer health plans. Founder and CEO Gary Becker was described on the company’s website as a “health insurance and risk management consultant for more than 30 years.”

ScriptSourcing had been on the FDA’s radar since at least 2022 for potential drug import violations, according to the affidavit. In August 2025, Dobbs, posing as someone interested in the AFP business, emailed ScriptSourcing and asked if the company was FDA-compliant.

A ScriptSourcing employee in responses to Dobbs said the company was FDA-compliant and that it had more than 2,000 name brand specialty medications and worked with more than 3,000 self-funded health plans.

However, that same year, the agency learned of two alleged incidents…



Read More:
How FDA built a case against CANARX execs offering cheap medication

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More